Treatment of pruritus of primary biliary cirrhosis with rifampin
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Pruritus can be a debilitating symptom in patients with chronic cholestasis. Based on previous reports of its efficacy, we evaluated the impact of rifampin on the pruritus associated with primary biliary cirrhosis. Fourteen patients were included in a randomized, crossover study. After a 15-day washout period, subjects were followed for three weeks. During the first and third week, patients received 600 mg of rifampin or placebo; no treatment was administered during the second week. Pruritus was subjectively scored on a scale from 0 to 100. With rifampin, pruritus disappeared in 11 patients and partially improved in three; with placebo, only two had a partial response (P less than 0.001). Six patients with a prior poor or no response to cholestyramine improved with rifampin. No changes in biochemical tests or side effects were observed during this period. We conclude that short-term administration of rifampin relieves pruritus in primary biliary cirrhosis. When administered over a period of eight months in an open study, the relief of pruritus was maintained, while one individual developed an allergic reaction. Rifampin appears to be a safe drug in the management of the pruritus of primary biliary cirrhosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although uncommon, drug-induced liver injuries-sometimes progressing to acute liver failure, hemolysis, renal impairment, and alteration in drug metabolism-have all been reported with rifampicin use such that use is avoided in patients with bilirubin levels greater than 2.5 mg/dL, with close follow-up warranted.(195,199)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [195]
In the citing paper
“Rifampicin, a pregnane X receptor agonist, has been used to successfully treat pruritus in patients with PBC in multiple small clinical trials at doses ranging from 150 mg daily to 300 mg twice daily.(193)(194)(195)(196)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [195]
In the citing paper
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [184]
Citations
Cites
The two‐period cross‐over clinical trial.
Hills, M., & Armitage, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb05903.x · Cited by 1,395
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
THE ESTIMATION OF ANTIPYRINE IN BIOLOGICAL MATERIALS
Brodie, B. B., Axelrod, J., Soberman, R., & Levy, B. B. (1949) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)56807-1 · Cited by 409
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231 · cited 7×
“Rifampin may rarely cause serious idiosyncratic hypersensitivity reactions, such as hemolytic anemia, renal failure, and thrombocytopenic purpura (9, 15-18).”
BackgroundInfluentialGrosset, J., & Leventis, S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s440 · Cited by 218 · cited 3×
“Up to 5% of individuals may have a moderate increase in transaminases, alkaline phosphatase, and bilirubin that normalize even in the presence of continued treatment (12).”
BackgroundRelief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 133 · cited 1×
“H~-histamine blockers (2-5) or procedures such as plasmapheresis and phototherapy (6, 7).”
BackgroundScheuer, P. J., & Lefkowitch, J. H. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199511000-00018 · Cited by 130
Scheuer, P. J., Lal, S., Summerfield, J. A., & Sherlock, S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92381-2 · Cited by 120
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120 · cited 1×
“H~-histamine blockers (2-5) or procedures such as plasmapheresis and phototherapy (6, 7).”
Background
Research works printed but not linked: 1
- Girling D: Hepatitis and other adverse reactions to antituberculous chemotherapy. Bull Int Union Tuber 51:8?12, 1980
Cited by
Items 101–200 of 266
An evidence‐based review of systemic treatments for itch
Pongcharoen, P., & Fleischer, A. B. (2015) · European Journal of Pain · doi:10.1002/ejp.766 · Cited by 40
Review article: pathophysiology and management of primary biliary cholangitis
Leung, K. K., Deeb, M., & Hirschfield, G. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16023 · Cited by 40
Review article: current and emerging therapies for the management of cirrhosis and its complications
Tapper, E. B., Ufere, N. N., Huang, D. Q., & Loomba, R. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16831 · Cited by 52
Islam, M. S., Sharif, A., Kwan, N., & Tam, K. C. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00007 · Cited by 43
Diagnostic and therapeutic approach to cholestatic liver disease
Perez, M. T., Serrano, P. L., Tomás, E., Gutiérrez, M. L. G., Lledó, J. L., Cacho, G., Santander, C., & Fernández‐Rodríguez, C. (2004) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082004000100008 · Cited by 45
“Two randomized, crossover, placebo-controlled studies have shown that 300-600 mg of rifampicin ameliorate pruritus in cholestasis (33,34).”
BackgroundMedical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 39
Primary biliary cirrhosis: new perspectives in diagnosis and treatment
Prince, M. I., & Jones, D. E. J. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.894.199 · Cited by 37
Liver disease in the mature horse
Pearson, E. G. (1999) · Equine Veterinary Education · doi:10.1111/j.2042-3292.1999.tb00927.x · Cited by 36
Tsankov, N., & Angelova, I. (2003) · Clinics in Dermatology · doi:10.1016/s0738-081x(02)00328-0 · Cited by 35
Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin
Ellis, E. C. S., Wagner, M., Lammert, F., Németh, A., Gumhold, J., Strassburg, C. P., Kylander, C., Katsika, D., Trauner, M. A., Einarsson, C., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.011 · Cited by 35
“Bilirubin was not significantly affected in the study populations mentioned [7–13], but there was a trend towards lower levels in one long-term study [12].”
BackgroundAn update on the physiopathology and therapeutic management of cholestatic pruritus in children
Thébaut, A., Debray, D., & Gonzales, E. M. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.08.007 · Cited by 36
Umeuchi, H., Kawashima, Y., Aoki, C. A., Kurokawa, T., Nakao, K., Itoh, M., Kikuchi, K., Kato, T., Okano, K., Gershwin, M. E., et al. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.06.019 · Cited by 35
Flumecinol for the treatment of pruritus associated with primary biliarg cirrhosis
TURNER, I. B., RAWLINS, M. D., WOOD, P., & JAMES, O. F. W. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00297.x · Cited by 34
Bhandari, B. M., Bayat, H., & Rothstein, K. D. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.03.008 · Cited by 36
Update on the Treatment of the Pruritus of Cholestasis
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.009 · Cited by 35
Balsells, F., Wyllie, R., Steffen, R. M., & Kay, M. H. (1997) · Clinical Pediatrics · doi:10.1177/000992289703600809 · Cited by 33
Effects and mechanisms of rifampin on hepatotoxicity of acetaminophen in mice
He, M., Zhang, S., Jiao, Y., Lin, X., Huang, J., Chen, C., Chen, Z., & Huang, R. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.06.020 · Cited by 32
Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Holtmeier, J., & Leuschner, U. (2001) · Digestion · doi:10.1159/000048854 · Cited by 34
Use of rifampin in nonstaphylococcal, nonmycobacterial disease
Morris, A. B., Brown, R. B., & Sands, M. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.1.1 · Cited by 32
Smith, H. T., de Souza, A. R., Thompson, A. H., McLaughlin, M., Dever, J. J., Myers, J. A., & Chen, J. V. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07862-z · Cited by 37
“1 3 treatment, which was maintained over 8 months (Table 3; [53]).”
BackgroundInfluentialthe Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, R., de Vries, E. S., Parés, A., Helder, J., Kemper, E. M., Zwinderman, K., Elferink, R. P. O., & Beuers, U. (2017) · Trials · doi:10.1186/s13063-017-1966-8 · Cited by 31
Variations of pharmacokinetics of drugs in patients with cirrhosis
Pena, M. Á., Horga, J. F., & Zapater, P. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1135733 · Cited by 31
Pruritus as a sign of systemic disease
Welz-Kubiak, K., Reszke, R., & Szepietowski, J. C. (2019) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2019.07.031 · Cited by 38
Natural history and management of primary biliary cirrhosis
Kumagi, T., & Al‐Harthy, N. (2012) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s25998 · Cited by 37
Stahl, S. H., Davies, M. R., Cook, D. I., & Graham, M. J. (2008) · Xenobiotica · doi:10.1080/00498250802105593 · Cited by 35
PXR as the tipping point between innate immune response, microbial infections, and drug metabolism
Bautista-Olivier, C. D., & Elizondo, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115147 · Cited by 30
Medical Palliation of the Jaundiced Patient with Pruritus
Bergasa, N. V. (2006) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.12.008 · Cited by 30
Advances in Pathogenesis and Treatment of Pruritus
Bolier, R., Elferink, R. P. J. O., & Beuers, U. H. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.11.006 · Cited by 34
Peripheral Neuronal Mechanism of Itch: Histamine and Itch
Histamine and Itch Robin L. Thurmond, K. K. (2014) · CRC Press eBooks · doi:10.1201/b16573-14 · Cited by 28
Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors
Marschall, H., Wagner, M., Zollner, G., & Trauner, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060133c · Cited by 30
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
Octreotide Acetate in Refractory Bone Marrow Transplant-Associated Diarrhea
Crouch, M. A., Restino, M. S., Cruz, J. M., Perry, J. J., & Hurd, D. D. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000401 · Cited by 27
Rifampicin therapy in severe forms of psoriasis
Tsankov, N., & Krasteva, M. (1992) · Journal of Dermatological Treatment · doi:10.3109/09546639209089062 · Cited by 27
Primary Biliary Cirrhosis: New Therapeutic Directions
Berg, C. L., & Gollan, J. L. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209095978 · Cited by 30
Lonsdale-Eccles, A. A., & Carmichael, A. (2003) · Drugs & Aging · doi:10.2165/00002512-200320030-00004 · Cited by 26
Treatment of the pruritus of cholestasis
Bergasa, N. V. (2004) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-004-0009-1 · Cited by 25
Ovadia, C., Lövgren‐Sandblom, A., Edwards, L. A., Langedijk, J., Geenes, V. L., Chambers, J., Cheng, F., Clarke, L., Begum, S., Noori, M., et al. (2018) · Journal of Clinical Apheresis · doi:10.1002/jca.21654 · Cited by 24
Understanding and Treating Pruritus in Primary Biliary Cholangitis
Carrion, A. F., Rosen, J. D., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.005 · Cited by 24
TSANKOV, N. K., & Kamarashev, J. A. (1993) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1993.tb02807.x · Cited by 24
Patel, A., Tapper, E. B., Kanwal, F., Woodrell, C. D., Hansen, L., Lai, J. C., Rogal, S. S., McDermott, C. L., Rakoski, M. O., & Ufere, N. N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000135 · Cited by 24
Rifampicin as treatment for pruritus in malignant cholestasis
Price, T. J., Patterson, W. K., & Olver, I. (1998) · Supportive Care in Cancer · doi:10.1007/s005200050210 · Cited by 23
Müllhaupt, B., Kullak-Ublick, G. A., Ambühl, P. M., Stocker, R., & Renner, E. L. (2003) · Hepatology Research · doi:10.1016/s1386-6346(02)00310-8 · Cited by 23
Update on Primary Biliary Cirrhosis
Heathcote, J. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/989486 · Cited by 24
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 22
Management of pre–liver transplantation patient—Part 2
Sharma, P., & Rakela, J. L. (2005) · Liver Transplantation · doi:10.1002/lt.20379 · Cited by 22
Moreno‐Otero, R., Lisker‐Melman, M., & Jones, E. A. (1989) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30645-9 · Cited by 22
Bergasa, N. V. (2014) · CRC Press eBooks · doi:10.1201/b16573-10 · Cited by 22
Pruritus in chronic liver disease: Mechanisms and treatment
Bergasa, N. V. (2004) · Current Gastroenterology Reports · doi:10.1007/s11894-004-0020-7 · Cited by 22
Extrahepatic Manifestations of Cholestatic Liver Diseases: Pathogenesis and Therapy
Pusl, T., & Beuers, U. H. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:147 · Cited by 22
Drug-Induced Liver Injury in the Setting of Chronic Liver Disease
Hoppmann, N. A., Gray, M. E., & McGuire, B. M. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.09.006 · Cited by 17
Use of Butorphanol as Treatment for Cholestatic Itch
Golpanian, R. S., Yosipovitch, G., & Levy, C. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06392-2 · Cited by 20
Primary biliary cirrhosis: Symptomatic treatment
Elias, E., & Burra, P. (1991) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1991.tb00912.x · Cited by 18
Bergasa, N. V. (1995) · Seminars in Dermatology · doi:10.1016/s1085-5629(05)80052-5 · Cited by 19
Sclerosing Cholangitis and Recurrent Pyogenic Cholangitis
Ross, A. S., & Kowdley, K. V. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00068-8 · Cited by 17
Pharmacological interventions for pruritus in adult palliative care patients
Boehlke, C. S., Joos, L., Couné, B., Becker, C., Meerpohl, J. J., Buroh, S., Hercz, D., Schwarzer, G., & Becker, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008320.pub4 · Cited by 28
Mittal, A. K. (2016) · Current problems in dermatology · doi:10.1159/000446057 · Cited by 17
Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy
Douglass, A., Wallace, K., Koruth, M., Barelle, C. J., Porter, A. J., & Wright, M. C. (2008) · Hepatology International · doi:10.1007/s12072-008-9093-y · Cited by 19
“Rifampicin is often given to patients with primary biliary cirrhosis (to control itch) and has been shown to reduce serum levels of alkaline phosphatase in patient trials [52, 53].”
BackgroundRole of Methotrexate in the Treatment of Chronic Cholestatic Disorders
Novak, K. L., & Swain, M. G. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.011 · Cited by 18
Benign Recurrent Intrahepatic Cholestasis: Treatment With S-Adenosylmethionine
Everson, G. T., Ahnen, D. J., Harper, P. C., & Krawitt, E. L. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80024-1 · Cited by 17
R eview : Treatment of primary biliary cirrhosis
Heathcote, J. (1996) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1996.tb00300.x · Cited by 18
The adverse effects of octreotide on the healing of colonic anastomoses in rats
Türkçapar, A. G., Demirer, S., Şengül, N., Ersöz, S., Kuterdem, E., Renda, N., & Kuzu, I. (1998) · Surgery Today · doi:10.1007/s005950050121 · Cited by 17
Drug Treatments for Pruritus in Adult Palliative Care
Siemens, W., Xander, C. J., Meerpohl, J. J., Antes, G., & Becker, G. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0863 · Cited by 20
Xu, C., Yue, R., Lv, X., Wang, S., & Du, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835991 · Cited by 17
Systematic review: efficacy of therapies for cholestatic pruritus
Ebhohon, E., & Chung, R. T. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231172829 · Cited by 18
Patil, A., & Mayo, M. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_9 · Cited by 18
Novel strategies and therapeutic options for the management of primary biliary cholangitis
Khanna, A., & Jones, D. E. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17728669 · Cited by 16
Mason, A. L., & Wasilenko, S. T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.006 · Cited by 16
DIAGNOSIS AND THERAPY OF CHOLESTATIC LIVER DISEASE
Pasha, T. M., & Lindor, K. D. (1996) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70477-6 · Cited by 17
Medina‐Morales, E., Barba, R., Gerger, H., Goyes, D., Trivedi, H. D., Ferrigno, B. W., Patwardhan, V. R., & Bonder, A. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001797 · Cited by 18
“…Placebo RR (95% CI) P References Cholestyramine Duncan 1984 4 3 1 6 4.00 (0.58, 27.41) 15 Rifampin Ghent 1988 0.5 9 0.5 9 1.00 (0.02, 45.39) 16 Podesta 1991 0.5 7 0.5 7 1.00 (0.02, 44.12) 21 Overall 1.00 (0.07, 14.70) 1.00 Fibrates Bezafibrate Corpechot 2018 43 7 45 5 0.96 (0.83, 1.10) 6 De…”
InfluentialCarbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
Elfaki, D., Bjornsson, E. S., & Lindor, K. D. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04104.x · Cited by 15
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 16
Hepatobiliary pruritus: What are effective treatments?
Connolly, C., Kantor, G. R., & Menduke, H. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)91818-3 · Cited by 15
Inflammation et métabolisme des médicaments
Pascussi, J., & Vilarem, M. (2008) · médecine/sciences · doi:10.1051/medsci/2008243301 · Cited by 13
An approach to the management of the pruritus of cholestasis
Bergasa, N. V. (2004) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00128-4 · Cited by 13
Saab, S., Han, S., & Martin, P. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70124-0 · Cited by 14
Proposed therapies in primary biliary cholangitis
Floreani, A., Sun, Y. H., Zou, Z. S., Li, B., Cazzagon, N., Bowlus, C. L., & Gershwin, M. E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1121810 · Cited by 14
Protective Effect of Rifampicin against Acute Liver Injury Induced by Carbon Tetrachloride in Mice
Huang, R., Okuno, H., Takasu, M., Shiozaki, Y., & Inoue, K. (1995) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.69.325 · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Droz, N., Thiebaut, M., Terrier, B., BEREZNE, A., Sogni, P., Beuvon, F., Guillevin, L., & Mouthon, L. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2013.02.034 · Cited by 11
Methylnaltrexone to Palliate Pruritus in Terminal Hepatic Disease
Hohl, C. M., Wong, J. K., & Harlos, M. (2015) · Journal of Palliative Care · doi:10.1177/082585971503100209 · Cited by 11
Ahmed, A., & Mayo, M. J. (2014) · Clinical gastroenterology · doi:10.1007/978-1-4939-1013-7_9 · Cited by 11
Saadi, M., Yu, C. H., & Othman, M. O. (2014) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2013.00021 · Cited by 14
Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis
Shah, R., & Kowdley, K. V. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679918 · Cited by 11
Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis
Dervout, C., Boulais, N., Barnetche, T., Nousbaum, J., Brenaut, E., & Misery, L. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.310 · Cited by 13
“(46) Rifampicin 300 mg twice daily Cross-over trial 14 VAS 0–100 mm Significant decrease in itch compared with placebo (p < 0.”
BackgroundBezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?
Dyson, J. K., & Jones, D. E. J. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.019 · Cited by 10
Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments
Gabrielli, F., Crepaldi, E., Cavicchioli, A., Rivi, M., Costanzo, A. A. C., Cursaro, C., & Andreoné, P. (2024) · Biomolecules · doi:10.3390/biom14101227 · Cited by 12
Terán, Á., Fábrega, E., & Pons‐Romero, F. (2009) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2009.07.006 · Cited by 10
Gui, L., Wu, Q., Hu, Y., Zeng, W., Tan, X., Zhu, P., Li, X., Yang, L., Jia, W. P., Liu, C., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00052 · Cited by 9
Antibiotics in cutaneous medicine: an update
Carter, E. L. (2003) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/s1085-5629(03)00046-4 · Cited by 10
Cherny, N. I. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh928 · Cited by 9
Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies
Kode, V., & Yimam, K. K. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00638-7 · Cited by 11
Treatment of primary sclerosing cholangitis
Rost, D., Kulaksiz, H., & Stiehl, A. (2007) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-007-0063-6 · Cited by 8
Skiba, G. H., Milkiewicz, P., Mutimer, D., BURNS, D. A., Marsden, J., & Elias, E. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00026.x · Cited by 8
Review of management of pruritus in palliative care
Alshammary, S. A., Duraisamy, B. P., & Alsuhail, A. (2016) · Journal of Health Specialties · doi:10.4103/1658-600x.173844 · Cited by 8
“Rifamipicin inhibits the uptake of bile acids by hepatocytes, and evidence suggests that it is second line of treatment for cholestatic pruritus, although the usage of this medication is unsatisfactory for most patients due to gastrointestinal side-effects such as constipation.[19-21] Rifamipicin is also consumed as a…”
BackgroundSymptom burden in chronic liver disease
Hassan, A., de León, I. H.-D., & Tapper, E. B. (2023) · Gastroenterology report · doi:10.1093/gastro/goae078 · Cited by 9
“While evidence on the efficacy of rifampicin for the treatment of cholestatic pruritus is limited, several studies to date suggest its potential efficacy [57–61].”
BackgroundKumagi, T., & Heathcote, E. J. (2008) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-008-0027-y · Cited by 7
Care of the Cholestatic Patient
Gossard, A. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.11.005 · Cited by 9
Stauber, R. E., Krisper, P., Zollner, G., Iberer, F., Beuers, U. H., & Trauner, M. (2004) · The International Journal of Artificial Organs · doi:10.1177/039139880402700411 · Cited by 7
Assessment of the Visual Analogue Score in the Evaluation of the Pruritus of Cholestasis
Bergasa, N. V., & Jones, E. A. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00001 · Cited by 12
Metadata
- Authors
- Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P.
- Affiliations
- Hospital Italiano de Buenos Aires (AR)
- Venue
- Digestive Diseases and Sciences
- Published
- 1991-02
- Volume
- 36
- Issue
- 2
- Pages
- 216-220
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2075314339
- Cited by
- 267
- References
- 31
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 12 · 2016: 9 · 2015: 14 · 2014: 8 · 2013: 6 · 2012: 9
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- pruritus, primary biliary cirrhosis, rifampicin, cholestasis, cholestyramine, pruritus management, drug safety, allergic reactions
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bilirubin, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Rifampin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.